文献速递产科母胎医学

糖基化纤连蛋白提高早孕期子痫前期预测效能

Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

本研究为嵌套病例对照研究,在亚洲中国单胎妊娠孕妇中于11-13周筛查子痫前期,回顾性检测存档血清糖基化纤连蛋白(GlyFn)。将GlyFn加入FMF三联试验后,早产型子痫前期筛查的AUC从0.859升至0.896,10%假阳性率下检出率从64.9%升至82.9%。

要点

  • ELISA与POC检测GlyFn的一致性相关系数为0.86(95%CI 0.83-0.88)。
  • 早产型子痫前期孕妇的中位GlyFn MoM显著高于非子痫前期孕妇(ELISA 1.23 vs 1.00,P<0.0001)。
  • GlyFn加入FMF三联试验后,早产型子痫前期筛查AUC显著提高(0.859 vs 0.896,P=0.012)。

核心结论

  • 在亚洲人群中,将GlyFn加入FMF三联试验可提高早产型和任何类型子痫前期的筛查灵敏度。
  • 作者认为需要前瞻性非干预研究来确认这些初步发现。

研究设计与样本

  • 本研究为嵌套病例对照研究,纳入2016年12月至2018年6月期间在11-13周妊娠接受子痫前期筛查的中国单胎妊娠孕妇。
  • 采用ELISA法回顾性检测1685例妊娠(含101例子痫前期)的存档血清GlyFn,采用POC设备检测448例妊娠(含101例子痫前期)的GlyFn。
  • 使用Lin一致性相关系数及Passing-Bablok和Bland-Altman分析评估ELISA与POC检测的一致性。
  • 将GlyFn转换为中位数倍数(MoM)以校正母体和妊娠特征,并使用FMF竞争风险模型估计子痫前期风险。

主要发现

  • ELISA与POC测量GlyFn的一致性相关系数为0.86(95%CI 0.83-0.88);Passing-Bablok分析提示存在比例偏倚(斜率1.08,95%CI 1.04-1.14),POC测得的GlyFn显著高于ELISA。
  • 非子痫前期妊娠中,ELISA测得的GlyFn与筛查时孕周无关(P=0.11),但与孕妇年龄(P<0.003)、体重(P<0.0002)、身高(P=0.001)、产次(P<0.02)和吸烟状态(P=0.002)显著相关。
  • 与非子痫前期妊娠相比,早产型子痫前期孕妇的中位GlyFn MoM显著升高(ELISA:1.23 vs 1.00,P<0.0001;POC:1.18 vs 1.00,P<0.0001)。
  • 与非子痫前期妊娠相比,足月型子痫前期孕妇的中位GlyFn MoM显著升高(ELISA:1.26 vs 1.00,P<0.0001;POC:1.22 vs 1.00,P<0.0001)。
  • GlyFn MoM与子痫前期分娩时孕周无关(P=0.989)。

关键数值与推荐

  • 在FMF三联试验基础上加入GlyFn筛查早产型子痫前期,AUC从0.859显著提高至0.896(P=0.012)。
  • 在10%固定假阳性率下,加入GlyFn后早产型子痫前期的检出率从64.9%(95%CI 48.7-81.1%)提高至82.9%(95%CI 66.4-93.4%)。
  • 在10%固定假阳性率下,加入GlyFn后任何类型子痫前期的检出率从52.5%(95%CI 42.3-62.5%)提高至65.4%(95%CI 55.2-74.5%)。

临床怎么用

  • 作者认为,在亚洲人群中,将GlyFn加入FMF三联试验可提高早产型和任何类型子痫前期的筛查灵敏度。
  • 作者指出需要前瞻性非干预研究来确认这些初步发现。

局限性

  • 作者指出需要前瞻性非干预研究来确认这些初步发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether maternal serum glycosylated fibronectin (GlyFn) level in the first trimester increases the sensitivity of the Fetal Medicine Foundation (FMF) triple test, which incorporates mean arterial pressure, uterine artery pulsatility index and placental growth factor, when screening for pre-eclampsia (PE) in an Asian population. METHODS: This was a nested case-control study of Chinese women with a singleton pregnancy who were screened for PE at 11-13 weeks' gestation as part of a non-intervention study between December 2016 and June 2018. GlyFn levels were measured retrospectively in archived serum from 1685 pregnancies, including 101 with PE, using an enzyme-linked immunosorbent assay (ELISA), and from 448 pregnancies, including 101 with PE, using a point-of-care (POC) device. Concordance between ELISA and POC tests was assessed using Lin's correlation coefficient and Passing-Bablok and Bland-Altman analyses. GlyFn was transformed into multiples of the median (MoM) to adjust for maternal and pregnancy characteristics. GlyFn MoM was compared between PE and non-PE pregnancies, and the association between GlyFn MoM and gestational age at delivery with PE was assessed. Risk for developing PE was estimated using the FMF competing-risks model. Screening performance for preterm and any-onset PE using different biomarker combinations was quantified by area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at a 10% fixed false-positive rate (FPR). Differences in AUC between biomarker combinations were compared using the DeLong test. RESULTS: The concordance correlation coefficient between ELISA and POC measurements was 0.86 (95% CI, 0.83-0.88). Passing-Bablok analysis indicated proportional bias (slope, 1.08 (95% CI, 1.04-1.14)), with POC GlyFn being significantly higher compared with ELISA GlyFn. ELISA GlyFn in non-PE pregnancies was independent of gestational age at screening (P = 0.11), but significantly dependent on maternal age (P < 0.003), weight (P < 0.0002), height (P = 0.001), parity (P < 0.02) and smoking status (P = 0.002). Compared with non-PE pregnancies, median GlyFn MoM using ELISA and POC testing was elevated significantly in those with preterm PE (1.23 vs 1.00; P < 0.0001 and 1.18 vs 1.00; P < 0.0001, respectively) and those with term PE (1.26 vs 1.00; P < 0.0001 and 1.22 vs 1.00; P < 0.0001, respectively). GlyFn MoM was not correlated with gestational age at delivery with PE (P = 0.989). Adding GlyFn to the FMF triple test for preterm PE increased significantly the AUC from 0.859 to 0.896 (P = 0.012) and increased the DR at 10% FPR from 64.9% (95% CI, 48.7-81.1%) to 82.9% (95% CI, 66.4-93.4%). The corresponding DRs at 10% FPR for any-onset PE were 52.5% (95% CI, 42.3-62.5%) and 65.4% (95% CI, 55.2-74.5%), respectively. CONCLUSIONS: Adding GlyFn to the FMF triple test increased the screening sensitivity for both preterm and any-onset PE in an Asian population. Prospective non-intervention studies are needed to confirm these initial findings. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Moungmaithong S, Wang X, Lau CSL, et al. Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2023. PMID: 37616523. doi:10.1002/uog.27451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。